Respiratory Syncytial Virus Therapeutics Market, By Treatment Type (Antiviral Drugs, Monoclonal Antibodies, and Vaccines), By Dosage Form, By Age Group, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Respiratory Syncytial Virus Therapeutics Market size was valued at US$ 1,590.32 Million in 2024, expanding at a CAGR of 15.50% from 2025 to 2032.
The Respiratory Syncytial Virus (RSV) therapeutics market focuses on developing treatments and preventive solutions for RSV infections, which primarily impact infants, older adults, and immunocompromised individuals. This market includes antiviral drugs, monoclonal antibodies, and vaccines designed to reduce disease severity and transmission. The rising incidence of RSV and increasing hospitalizations have fueled demand for effective therapies. Governments and pharmaceutical companies are investing in research to develop advanced treatments, such as long-acting monoclonal antibodies and innovative antivirals. Regulatory approvals for RSV vaccines, particularly for high-risk populations, have further expanded market opportunities. Advancements in diagnostic technologies enable early detection and timely intervention, improving patient outcomes. North America and Europe lead the market due to well-established healthcare infrastructure and high awareness, while emerging economies are witnessing growing adoption. Collaborations between biotech firms and healthcare organizations drive innovation, and the introduction of cost-effective therapies is expected to improve accessibility, ensuring better global disease management.
Respiratory Syncytial Virus Therapeutics Market- Market Dynamics
Ø Increasing adoption of long-acting monoclonal antibodies for infant RSV protection.
The growing adoption of long-acting monoclonal antibodies for infant RSV protection is a major driver of the RSV therapeutics market. Traditional monoclonal antibodies like Palivizumab required monthly dosing, limiting accessibility and compliance. However, newer long-acting antibodies such as Nirsevimab provide extended protection with a single dose, enhancing convenience and cost-effectiveness. Governments and healthcare organizations are increasingly recommending these therapies for high-risk infants to reduce RSV-related hospitalizations. The significant burden of RSV infections in newborns and premature infants has led to expanded immunization programs. Additionally, regulatory approvals and increased funding are improving the availability of long-acting monoclonal antibodies in both developed and emerging markets. As these therapies become more widely integrated into routine infant care, they are expected to drive substantial market growth.
Respiratory Syncytial Virus Therapeutics Market- Segmentation Analysis:
The Global Respiratory Syncytial Virus Therapeutics Market is segmented based on Treatment Type, Dosage Form, Age Group, Distribution Channel, and Region.
The market is divided into three categories based on Treatment Type: Antiviral Drugs, Monoclonal Antibodies, and Vaccines. The monoclonal antibodies segment leads the Respiratory Syncytial Virus (RSV) therapeutics market due to its proven efficacy in preventing severe infections, particularly in high-risk populations such as infants and older adults. While Palivizumab has been a longstanding option, the recent approval of long-acting antibodies like Nirsevimab has further strengthened this segment. These therapies offer passive immunity, significantly reducing RSV-related hospitalizations and complications. Rising RSV infection rates and government recommendations for monoclonal antibody use in vulnerable groups have driven demand. Pharmaceutical companies are actively developing next-generation antibodies with enhanced efficacy and longer-lasting protection. Additionally, the high cost of these therapies substantially contributes to market revenue. North America and Europe dominate adoption, supported by strong healthcare infrastructure and reimbursement policies. As more antibody formulations gain regulatory approval, this segment is expected to maintain its leadership in the RSV therapeutics market.
The market is divided into three categories based on Dosage Form: Oral, Injectable, and Inhalation. The injectable segment leads the Respiratory Syncytial Virus (RSV) therapeutics market, driven by the widespread use of monoclonal antibodies and vaccines, which primarily rely on injectable formulations. Monoclonal antibodies such as Palivizumab and Nirsevimab, along with newly approved RSV vaccines for older adults, require injection for effective delivery, ensuring precise dosing, rapid absorption, and prolonged protection. The increasing incidence of severe RSV infections in infants and older adults has accelerated the adoption of injectable treatments. Government immunization programs and hospital protocols further support this trend by prioritizing injectable RSV therapies. North America and Europe dominate this segment due to their strong healthcare infrastructure and high vaccine coverage. With the approval of more long-acting monoclonal antibodies and RSV vaccines, the injectable segment is expected to maintain its leadership in the RSV therapeutics market.
Respiratory Syncytial Virus Therapeutics Market- Geographical Insights
North America leads the Respiratory Syncytial Virus (RSV) therapeutics market, driven by high awareness, advanced healthcare infrastructure, and the widespread adoption of monoclonal antibodies and vaccines. The United States dominates the region, supported by government-backed immunization programs and regulatory approvals for cutting-edge RSV therapies such as Nirsevimab and RSV vaccines for older adults. The rising number of RSV-related hospitalizations among infants and the elderly has intensified demand for effective treatments.
Additionally, major pharmaceutical companies are actively investing in research and development to introduce next-generation monoclonal antibodies, further strengthening market growth. Favorable reimbursement policies and high healthcare expenditures contribute to the market’s expansion. The U.S., in particular, benefits from a strong regulatory framework, with organizations like the CDC and FDA facilitating the adoption of RSV therapeutics. As government initiatives and clinical advancements continue, North America is expected to maintain its dominance in the RSV therapeutics market.
Respiratory Syncytial Virus Therapeutics Market- Competitive Landscape:
The Respiratory Syncytial Virus (RSV) therapeutics market is highly competitive, driven by extensive research and development (R&D), strategic partnerships, and regulatory approvals. Leading pharmaceutical companies such as AstraZeneca, Sanofi, Pfizer, GSK, and Moderna are at the forefront, developing innovative RSV therapies, including monoclonal antibodies, vaccines, and antiviral drugs to address the rising burden of RSV infections.
Strategic collaborations and acquisitions play a key role in market expansion, as seen in Pfizer’s acquisition of ReViral to strengthen its RSV antiviral pipeline. The approval of long-acting monoclonal antibodies like Nirsevimab and RSV vaccines for older adults has heightened competition, prompting companies to focus on clinical trials, government collaborations, and competitive pricing strategies. As demand for RSV prevention and treatment continues to grow, the market is expected to see increased innovation, new entrants, and the introduction of more advanced therapeutic solutions.
Recent Developments:
v In February 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted priority review for its application to expand the indication of its respiratory syncytial virus (RSV) vaccine to individuals aged 50 to 59 at higher risk of RSV-related illness. This move aligns with efforts to broaden protection against RSV in vulnerable populations.
v In May 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract illness caused by RSV in individuals aged 60 and older. This approval has strengthened Pfizer’s position in the RSV therapeutics market and contributed to its revenue growth.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Ø AstraZeneca plc
Ø Sanofi S.A.
Ø Pfizer Inc.
Ø Moderna, Inc.
Ø GSK plc
Ø Merck & Co., Inc.
Ø Johnson & Johnson
Ø Novavax, Inc.
Ø Bavarian Nordic A/S
Ø Enanta Pharmaceuticals, Inc.
Ø BioNTech SE
Ø Meissa Vaccines, Inc.
Ø Codagenix, Inc.
Ø Alnylam Pharmaceuticals, Inc.
Ø Vaxart, Inc.
Ø Icosavax, Inc.
GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
Ø Antiviral Drugs
Ø Monoclonal Antibodies
Ø Vaccines
GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032
Ø Oral
Ø Injectable
Ø Inhalation
GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032
Ø Infants & Young Children
Ø Adults
Ø Older Adults (65+ years)
GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Ø Hospitals & Clinics
Ø Retail Pharmacies
Ø Online Pharmacies
GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
Ø North America
o U.S.
o Canada
Ø Europe
o Germany
o UK
o France
o Italy
o Spain
o The Netherlands
o Sweden
o Russia
o Poland
o Rest of Europe
Ø Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Thailand
o Philippines
o Rest of APAC
Ø Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
Ø The Middle East and Africa
o Saudi Arabia
o UAE
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Respiratory Syncytial Virus Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Respiratory Syncytial Virus Therapeutics Market Snippet by Treatment Type
2.1.2. Respiratory Syncytial Virus Therapeutics Market Snippet by Dosage Form
2.1.3. Respiratory Syncytial Virus Therapeutics Market Snippet by Age Group
2.1.4. Respiratory Syncytial Virus Therapeutics Market Snippet by Distribution Channel
2.1.5. Respiratory Syncytial Virus Therapeutics Market Snippet by Country
2.1.6. Respiratory Syncytial Virus Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Respiratory Syncytial Virus Therapeutics Key Market Trends
3.1. Respiratory Syncytial Virus Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Respiratory Syncytial Virus Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Respiratory Syncytial Virus Therapeutics Market Opportunities
3.4. Respiratory Syncytial Virus Therapeutics Market Future Trends
4. Respiratory Syncytial Virus Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Respiratory Syncytial Virus Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Respiratory Syncytial Virus Therapeutics Market Landscape
6.1. Respiratory Syncytial Virus Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Respiratory Syncytial Virus Therapeutics Market – By Treatment Type
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
7.1.2. Antiviral Drugs
7.1.3. Monoclonal Antibodies
7.1.4. Vaccines
8. Respiratory Syncytial Virus Therapeutics Market – By Dosage Form
8.1. Overview
8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
8.1.2. Oral
8.1.3. Injectable
8.1.4. Inhalation
9. Respiratory Syncytial Virus Therapeutics Market – By Age Group
9.1. Overview
9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
9.1.2. Infants & Young Children
9.1.3. Adults
9.1.4. Older Adults (65+ years)
10. Respiratory Syncytial Virus Therapeutics Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
10.1.2. Hospitals & Clinics
10.1.3. Retail Pharmacies
10.1.4. Online Pharmacies
11. Respiratory Syncytial Virus Therapeutics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.8. The U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Respiratory Syncytial Virus Therapeutics Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AstraZeneca plc
12.2.2. Sanofi S.A.
12.2.3. Pfizer Inc.
12.2.4. Moderna, Inc.
12.2.5. GSK plc
12.2.6. Merck & Co., Inc.
12.2.7. Johnson & Johnson
12.2.8. Novavax, Inc.
12.2.9. Bavarian Nordic A/S
12.2.10. Enanta Pharmaceuticals, Inc.
12.2.11. BioNTech SE
12.2.12. Meissa Vaccines, Inc.
12.2.13. Codagenix, Inc.
12.2.14. Alnylam Pharmaceuticals, Inc.
12.2.15. Vaxart, Inc.
12.2.16. Icosavax, Inc.
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
